AstraZeneca Collaborates with Eko to Advance the Digital Health Tools for the Diagnosis of CV Diseases

 AstraZeneca Collaborates with Eko to Advance the Digital Health Tools for the Diagnosis of CV Diseases

Shots:

  • The two companies collaborated to facilitate the development of digital health tools for the earlier screening of cardiovascular diseases, including HF
  • AstraZeneca and Eko will accelerate the development of Eko algorithms, enhancing clinical trials with Eko technology, and potentially building new HF detection solutions. The agreement allows the companies to harness the potential to improve access to individualized care and generate better patient outcomes
  • In Dec’2019, Eko has received the US FDA’s BT designation for a novel ECG-based algorithm that can identify reduced LVEF. If approved, the algorithm will be compatible with the DUO, Eko’s handheld stethoscope, and ECG device

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Physician Practice

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post